Products for Research Use Only

Mardepodect

CAT: 0804-HY-50098-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-50098-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Mardepodect (PF-2545920) is a potent, orally active and selective PDE10A inhibitor with an IC50 of 0.37 nM, with >1000-fold selectivity over other PDEs. Mardepodect can cross the blood-brain barrier[1][2].
CAS Number
898562-94-2
Product Name Alternative
PF-2545920
UNSPSC
12352005
Hazard Statement
H302, H315, H319
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/PF-2545920.html
Purity
98.81
Solubility
DMSO : ≥ 45 mg/mL
Smiles
CN(N=C1C2=CC=C(OCC3=NC4=CC=CC=C4C=C3)C=C2)C=C1C5=CC=NC=C5
Molecular Formula
C25H20N4O
Molecular Weight
392.45
Precautions
H302, H315, H319
References & Citations
[1]Verhoest PR, et al. Discovery of a novel class of phosphodiesterase 10A inhibitors and identification of clinical candidate 2-[4- (1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl) -phenoxymethyl]-quinoline (PF-2545920) for the treatment of schizophrenia. J Med Chem, 2009, 52 (16), 5188-5196.|[2]Grauer SM, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther, 2009, 331 (2), 574-590.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
PDE10
Citation 01
BioRxiv. 2025 March 17.|Toxicol Appl Pharmacol. 2024 May:486:116945.|Patent. US20230111925A1.